CL2022001731A1 - Inhibidores de egfr. - Google Patents

Inhibidores de egfr.

Info

Publication number
CL2022001731A1
CL2022001731A1 CL2022001731A CL2022001731A CL2022001731A1 CL 2022001731 A1 CL2022001731 A1 CL 2022001731A1 CL 2022001731 A CL2022001731 A CL 2022001731A CL 2022001731 A CL2022001731 A CL 2022001731A CL 2022001731 A1 CL2022001731 A1 CL 2022001731A1
Authority
CL
Chile
Prior art keywords
egfr inhibitors
useful
present disclosure
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
CL2022001731A
Other languages
English (en)
Inventor
Emmerson Campbell John
A Dineen Thomas
Brooijmans Natasja
D Brubaker Jason
Suzanne Eno Meredith
L Kim Joseph
Ozen Aysegul
Perola Emanuele
D Williams Brett
Wilson Douglas
J Wilson Kevin
De Savi Christopher
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of CL2022001731A1 publication Critical patent/CL2022001731A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present disclosure provides a compound represented by structural formula (I) : or a pharmaceutically acceptable salt thereof useful for treating a cancer.
CL2022001731A 2019-12-23 2022-06-23 Inhibidores de egfr. CL2022001731A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962953030P 2019-12-23 2019-12-23

Publications (1)

Publication Number Publication Date
CL2022001731A1 true CL2022001731A1 (es) 2023-07-14

Family

ID=74186977

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001731A CL2022001731A1 (es) 2019-12-23 2022-06-23 Inhibidores de egfr.

Country Status (19)

Country Link
US (2) US20230056541A1 (es)
EP (1) EP4081515A1 (es)
JP (1) JP2023508976A (es)
KR (1) KR20230005112A (es)
CN (1) CN115135642A (es)
AR (1) AR121044A1 (es)
AU (1) AU2020412710A1 (es)
BR (1) BR112022012585A2 (es)
CA (1) CA3163007A1 (es)
CL (1) CL2022001731A1 (es)
CO (1) CO2022010317A2 (es)
CR (1) CR20220354A (es)
EC (1) ECSP22057865A (es)
IL (1) IL294251A (es)
MX (1) MX2022007969A (es)
PE (1) PE20221264A1 (es)
TW (1) TW202138364A (es)
UY (1) UY39002A (es)
WO (1) WO2021133809A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL294251A (en) * 2019-12-23 2022-08-01 Blueprint Medicines Corp Inhibitors of mutant forms of egfr
JP2023510918A (ja) 2020-01-15 2023-03-15 ブループリント メディシンズ コーポレイション Ｍａｐ４ｋ１阻害剤
WO2022192431A1 (en) 2021-03-10 2022-09-15 Blueprint Medicines Corporation Egfr inhibitors
IL306100A (en) 2021-04-13 2023-11-01 Nuvalent Inc Amino-substituted heterocycles for the treatment of cancer with EGFR mutations
CA3223859A1 (en) * 2021-06-23 2022-12-29 Erika BUTLER Salt and crystal forms of an epidermal growth factor receptor inhibitor
WO2022271801A1 (en) * 2021-06-23 2022-12-29 Blueprint Medicines Corporation Process for preparing egfr inhibitors
WO2023283130A1 (en) * 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
CN117940406A (zh) * 2021-07-15 2024-04-26 缆图药品公司 Map4k1抑制剂
EP4393916A1 (en) * 2021-08-27 2024-07-03 Shanghai Hansoh Biomedical Co., Ltd. Nitrogen-containing heterocyclic derivative inhibitor, and preparation method therefor and use thereof
WO2023071998A1 (zh) * 2021-10-26 2023-05-04 杭州德睿智药科技有限公司 新型嘧啶或三嗪取代吡啶并杂环化合物
CN116159062A (zh) * 2021-11-24 2023-05-26 上海艾力斯医药科技股份有限公司 药物组合物及其用途
WO2023134266A1 (zh) * 2022-01-17 2023-07-20 苏州浦合医药科技有限公司 2-哌啶基或2-吡唑基取代的嘧啶化合物作为egfr抑制剂
TW202400579A (zh) * 2022-03-17 2024-01-01 大陸商上海翰森生物醫藥科技有限公司 含氮雜環類衍生物抑制劑、其製備方法和應用
WO2023183354A1 (en) 2022-03-22 2023-09-28 Blueprint Medicines Corporation Blu-945 in combination with osimertinib for the treatment of non-small-cell lung cancer
TW202404590A (zh) 2022-04-05 2024-02-01 美商纜圖藥品公司 Ｅｇｆｒ抑制劑
WO2023241618A1 (zh) * 2022-06-14 2023-12-21 南京明德新药研发有限公司 氨基嘧啶类化合物及其应用
WO2024008048A1 (zh) * 2022-07-04 2024-01-11 杭州德睿智药科技有限公司 新型嘧啶或三嗪取代吡啶并杂环化合物
WO2024059169A1 (en) 2022-09-14 2024-03-21 Blueprint Medicines Corporation Egfr inhibitors
CN115650958B (zh) * 2022-10-14 2024-05-17 中国药科大学 2-氨基嘧啶类化合物及其制备方法、用途和药物组合物
CN115626939B (zh) * 2022-12-01 2023-06-16 北京鑫开元医药科技有限公司 一种egfr降解剂、制备方法、药物组合物及其应用
CN116969923B (zh) * 2023-01-18 2024-07-30 北京鞍石生物科技股份有限公司 杂芳基氨基化合物及其制备方法和应用
CN115974845B (zh) * 2023-01-19 2024-09-20 奥锐特药业股份有限公司 奥希替尼中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130225528A1 (en) 2008-05-21 2013-08-29 Ariad Pharmaceuticals, Inc. Phosphorus Derivatives as Kinase Inhibitors
WO2010129053A2 (en) 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
WO2014074675A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
CN104955824B (zh) 2012-11-20 2017-09-22 豪夫迈·罗氏有限公司 作为含t790m的egfr突变体的抑制剂的氨基嘧啶化合物
EP3052494B1 (en) * 2013-06-28 2018-12-26 H. Hoffnabb-La Roche Ag Azaindazole compounds as inhibitors of t790m containing egfr mutants
AU2017232516B2 (en) 2016-03-16 2023-01-19 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
CN111295384B (zh) 2018-10-10 2022-08-12 江苏豪森药业集团有限公司 双环类衍生物抑制剂、其制备方法和应用
CN112409331B (zh) 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
IL294251A (en) * 2019-12-23 2022-08-01 Blueprint Medicines Corp Inhibitors of mutant forms of egfr
JP2023510918A (ja) 2020-01-15 2023-03-15 ブループリント メディシンズ コーポレイション Ｍａｐ４ｋ１阻害剤

Also Published As

Publication number Publication date
KR20230005112A (ko) 2023-01-09
CA3163007A1 (en) 2021-07-01
IL294251A (en) 2022-08-01
ECSP22057865A (es) 2022-11-30
JP2023508976A (ja) 2023-03-06
CR20220354A (es) 2022-12-19
BR112022012585A2 (pt) 2022-09-27
CN115135642A (zh) 2022-09-30
MX2022007969A (es) 2022-12-13
PE20221264A1 (es) 2022-08-16
AU2020412710A1 (en) 2022-08-11
AR121044A1 (es) 2022-04-13
US20230026209A1 (en) 2023-01-26
US20230056541A1 (en) 2023-02-23
WO2021133809A1 (en) 2021-07-01
EP4081515A1 (en) 2022-11-02
UY39002A (es) 2021-07-30
US11718602B2 (en) 2023-08-08
TW202138364A (zh) 2021-10-16
CO2022010317A2 (es) 2022-10-21

Similar Documents

Publication Publication Date Title
CL2022001731A1 (es) Inhibidores de egfr.
EA202193015A1 (ru) Ингибиторы cdk
PH12020500673A1 (en) Compounds
MX2024000230A (es) Inhibidores de cdk2.
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина
EA201170872A1 (ru) Ингибиторы протеинкиназы
EA201792320A1 (ru) Способ лечения рака ингибитором пути stat3 и ингибитором киназы
EA201991241A1 (ru) Способ получения метоксиметилпиридин дикарбоксилата
MY193239A (en) Novel b-lactamase inhibitors
EA201990952A1 (ru) ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met
CO2024000221A2 (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
PH12018500999A1 (en) Sodium channel blocker
EA202192760A1 (ru) Трициклические соединения
EA202190989A1 (ru) Новый способ синтеза производных пиперазинил-этокси-бромфенила и их применение в получении содержащих их соединений
UY39662A (es) Inhibidores de egfr
MX2020011991A (es) Inhibidores de la oncoproteina ras, metodos de produccion y metodos de uso de los mismos.
EA202090438A1 (ru) Производные глицерретиновой кислоты для лечения гиперкалиемии
MX2022006984A (es) Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina.
EA202193248A1 (ru) ТЕТРАЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Cdc7
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam